Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

– Actively recruiting in three Phase 1b/2 clinical trials (one of which is in Phase 2) – Recently completed first cohort in Phase 1b/2 trial evaluating Annamycin in combination with cytarabine (Ara-C) for the treatment of acute myeloid leukemia (AML); Preliminary results show a durable complete response at starting dose level in an elderly subject – Multiple expected milestones and interim data readouts expected in 2023 HOUSTON, May 10, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today provided an update on recent activity and expected near term milestones across its clinical development pipeline.

The release as fetched from its publisher. moleculin.com ↗